Autism Therapeutics is in the final stages of clinical development for a new drug which, if FDA approved, would provide treatment for the unmet medical need of autistic patients suffering with repetitive behaviors.
There are currently no FDA approved treatments for a core symptom of autism and there remains a clear unmet medical need.
Autism Therapeutics views the heterogeneity in autism as a guiding principle rather than an impediment to precise and conscientious drug development.
Autism Therapeutics has pioneered new clinical trial design strategies aimed at addressing commonly confounding issues of heterogeneity in autism clinical trials.
ATOO1 is in the final stages of development for a core symptom of autism (repetitive behaviors). Numerous clinical studies have indicated that AT001 has the potential to be a safe and effective treatment for patients suffering with this condition.
Autism (referred to in DSM IV as autistic disorder) is a Pervasive Developmental Disorder (PDD). Related developmental disorders defined in the DSM-IV are Asperger’s Disorder and Pervasive Developmental Disorder – Not Otherwise Specified (PPD-NOS). Together these three are sometimes called Autistic Spectrum Disorder (ASD), or simply autism.
For more information on recent news, updates, and press releases, as well as other current information relevant to Autism Therapeutics, please visit our Media Center. You can also find relevant publications and research there.